We are investigating a new monoclonal antibody, OSE-279, for patients with advanced solid tumors or lymphomas. The study aims to find the best dose and evaluate its safety and effectiveness compared to existing treatments.
Health conditions and diseases that the clinical trial is designed to study and treat.
Stage IV Non-Small Cell Lung Cancer (NSCLC) is the most advanced form of lung cancer, where the cancer has spread beyond the lungs to other parts of the body, often leading to severe symptoms and requiring aggressive treatment.
Advanced solid tumors refer to cancers that have progressed to a late stage, where they have spread to other parts of the body, making treatment more complex and often requiring specialized therapies.
Lymphoma is a type of cancer that originates in the lymphatic system, which is part of the immune system, and can cause symptoms like swollen lymph nodes, fever, and weight loss.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
